Navigation Links
Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats

First Scientific Presentation for Pristiq Occurs at the 55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists

COLLEGEVILLE, Pa., May 09, 2007 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , presented results from the first Phase 3 studies evaluating Pristiq(TM) (desvenlafaxine) for the treatment of moderate-to-severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. These studies showed that women who took Pristiq experienced a reduction in both the number and severity of hot flashes. Additional analyses presented demonstrated that Pristiq reduced the number of nighttime awakenings and mood disturbances in postmenopausal women with hot flashes and night sweats and did not have a negative effect on sexual function.

The data were presented at the 55th Annual Meeting of the of Obstetricians and Gynecologists (ACOG) in San Diego. Pristiq is currently under review by the U.S. Food and Drug Administration (FDA) and could be the first non-hormonal treatment for menopausal hot flashes and night sweats.

"Millions of women experience hot flashes and night sweats during menopause, but there are currently no effective non-hormonal treatment options approved by the FDA," says Joseph Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals. "The data indicate Pristiq has the potential to expand the range of effective treatment options by providing a non-hormonal choice for menopausal women with moderate-to-severe vasomotor symptoms."

Evaluation of Safety and Efficacy

Three studies presented examine the efficacy of Pristiq at various doses while also evaluating its safety and tolerability profile. The most common side effect in all three studies was nausea, which was generally mild to moderate, was dose-dependent, and resolved quickly, on average within three days.

Efficacy and Safe
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:8/21/2014)... -- The board of directors of VirtualScopics, Inc. (NASDAQ: ... imaging solutions, today announced that James Groff , ... Mr. Groff has held the role of acting chief ... January 2006 as an accounting manager and was promoted ... board of VirtualScopics asked Jim to assume the role ...
(Date:8/21/2014)... HOUSTON, Aug. 21, 2014  Cyberonics, Inc. (NASDAQ: ... 25, 2014.  Quarterly highlights 1   ... compared to the first quarter of fiscal 2014, and other ... million, an increase of 6.8%; , Strong international net ... constant currency basis; , U.S. net product sales reached ...
(Date:8/20/2014)... , Aug. 20, 2014 Northstar ... announced that after months of hard work from ... the new Snorenz formulation and package design.  The ... and B-6 back into the product due to ... longer lasting effects.  Snorenz Nighttime will also include ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... Ala., Nov. 19 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ... 5,000,000 shares of its common stock at $9.75 per share, ... the shares are being offered by BioCryst pursuant to an ... Exchange Commission. BioCryst has also granted the underwriters a ...
... , TAINAN, ... global,supplier of active pharmaceutical ingredients (APIs), announced that ... Certification from,SafeBridge(R) Consultants, Inc. The Certification confirms ScinoPharm,s,competency ... active,pharmaceutical ingredients (APIs), and applies to specific laboratories ...
Cached Medicine Technology:BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2
(Date:8/21/2014)... News) -- Being born at a low birth weight puts ... new study suggests. The findings may partly explain high ... high prevalence of low birth weight, the researchers added. ... those with a low birth weight were 13 percent more ... normal birth weight. The risk of diabetes was 40 percent ...
(Date:8/21/2014)... 21, 2014 The W. Montague ... and a national voice in the elimination of ... disparities during the 112th National Medical Association’s (NMA) ... included: , John Ruffin, Ph.D, former Director of ... Disparities, whose life-long career and innovations have had ...
(Date:8/21/2014)... WA (PRWEB) August 21, 2014 ... Mulanax at Eastlake Chiropractic and Massage Center ... the Center’s growing team. Rina Lang, LMP and ... a wide range of massage techniques, and have developed ... settings. This is particularly important in a clinical ...
(Date:8/21/2014)... SAN FRANCISCO Aug. 21, 2014 Researchers in ... for congenital cataracts can quickly and accurately diagnose a ... to a study published online today in ... of Ophthalmology. Using a single test, doctors were ... based on their mutations reducing the time and money ...
(Date:8/21/2014)... August 21, 2014 The world wound ... billion in 2014 and reach USD 18.3 billion by ... period. The drivers of such growth include governments’ contribution ... and diabetic population, and surging ageing population. However, the ... wound care products. Region-wise, North America leads the global ...
Breaking Medicine News(10 mins):Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3
... Home Workers in PA, MI, IL, FL, OH, MD, WI, WA Join Forces ... Private Equity ... Buyout, WASHINGTON, Oct. 3 ... workers union today,is launching a multi-state grassroots campaign calling on global buyout,giant the ...
... quit, researchers say , WEDNESDAY, Oct. 3 (HealthDay News) ... linked to nicotine dependence and to the anxiety and ... Scripps Research Institute in La Jolla, Calif., said the ... smokers kick the habit. , In rats, chronic nicotine ...
... 3 The following is a,statement of William ... President Bush today let down America,s children and ... legislation that would,increase the federal cigarette tax by ... Children,s Health Insurance Program (SCHIP). The President has ...
... Conn., Oct. 3 ,Unilens Vision Inc. (OTC Bulletin Board: ... that Eschenbach Optik has been named,the exclusive worldwide distributor ... Inc. will serve as the exclusive distributor,for North and ... be the,exclusive distributor in the rest of the world. ...
... and Revitalization, ORLANDO, Fla., Oct. 3 ... PRZ ), one of the nation,s leading providers,of ... issued,the following corporate update detailing recent developments that ... refined long term,growth strategy. Specifically, Lubinsky stated: ...
... Education Campaign Urges Enrollment, LOS ANGELES, Oct. 3 ... of clinical trials are being conducted to seek a,treatment, ... potentially fatal,autoimmune disease that affects more than 1.5 million ... key question that clinical trials answer is, "Will this ...
Cached Medicine News:Health News:SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's Largest Nursing Home Chain 2Health News:Rat Study Gets at Root of Nicotine Addiction 2Health News:President's Veto of Bill to Increase Cigarette Tax, Fund SCHIP Benefits Big Tobacco at Expense of America's Kids 2Health News:Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens 2Health News:Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens 3Health News:PainCare Reports on Key Corporate Developments 2Health News:PainCare Reports on Key Corporate Developments 3Health News:PainCare Reports on Key Corporate Developments 4Health News:PainCare Reports on Key Corporate Developments 5Health News:Clinical Trials for Lupus Underway After Decades of Drought 2
... Reichert TONO-PEN AVIA tonometer is an ... readings that correlate strongly with Goldmann ... ergonomic design and advanced electronic measurement ... fast and accurate IOP measurements with ...
... Delivery System is a ... to assemble brachytherapy seeds, ... into seed trains of ... variable seed to seed ...
... from innovative research in materials and technologies ... the aerospace and automotive industry, the high- ... footwear and textile industry. , ,This know-how ... Carrera sunglasses collection to create unique and ...
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Medicine Products: